Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Overexpression of growth differentiation factor 15 (GDF15) by bone marrow mesenchymal stem cells occurs widely in patients with multiple myeloma, but the pathophysiologic effects of GDF15 in this setting remain undefined. GDF15 has been described in numerous solid tumors but never in hematologic malignancies. In this study, we report that GDF15 significantly increases survival of stroma-dependent multiple myeloma cells including primary multiple myeloma cells. In particular, GDF15 conferred resistance to melphalan, bortezomib, and to a lesser extent, lenalidomide in both stroma-dependent and stroma-independent multiple myeloma cells. Akt-dependent signaling was critical to mediate the effects of GDF15, whereas Src and extracellular signal-regulated kinase 1/2 signaling pathways were not involved. Given these results, we tested the clinical significance of plasma concentrations of GDF15 (pGDF15) in 131 patients with multiple myeloma and found that it correlated with disease prognosis. Specifically, patients with high levels of pGDF15 had lower probabilities of event-free and overall survival 30 months after diagnosis than patients with low pGDF15 levels. Our findings suggest that tumor microenvironment-derived GDF15 is a key survival and chemoprotective factor for multiple myeloma cells, which is pathophysiologically linked to both initial parameters of the disease as well as patient survival. Cancer Res; 72(6); 1395–406. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 2×
“The disease is fatal and the median survival is 5 years (2), but this survival has significantly increased with the introduction of novel therapies, (3) with some patients surviving more than 10 years (4).”
BackgroundSelf-citationLarge-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum
Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530278100 · Cited by 503 · cited 1×
“Although the overexpression of GDF15 has been described in numerous solid malignancies (26, 29, 32, 37), its precise implication in tumors remains unknown.”
BackgroundBiologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 2×
“22 78 (60) High Dose Chemotherapy 53 (40) Melphalan-Prednisone Treatment (no.”
BackgroundBone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Self-citationHsiao, E. C., Koniaris, L. G., Zimmers-Koniaris, T., Sebald, S. M., Huynh, T. V., & Lee, S.-J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.10.3742-3751.2000 · Cited by 302
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer
Bauskin, A. R., Brown, D. A., Kuffner, T., Johnen, H., Luo, X. W., Hunter, M., & Breit, S. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4067 · Cited by 251 · cited 1×
“GDF15 may have different functions in cancer, such as being a tumor suppressor during early oncogenesis but a promoter at later stages (22, 38).”
BackgroundArnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190 · cited 2×
“Abnormalities of BM-MSCs have recently been reported (19-21).”
BackgroundBaek, S. J., Okazaki, R., Lee, S.-H., Martinez, J., Kim, J.-S., Yamaguchi, K., Mishina, Y., Martin, D. W., Shoieb, A., Mcentee, M. F., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.015 · Cited by 175
Cited by
Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
Wischhusen, J., Melero, I., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00951 · Cited by 506
Targeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
Unsicker, K., Spittau, B., & Krieglstein, K. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.003 · Cited by 274
Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy
Duan, C.-W., Shi, J., Chen, J., Wang, B., Yu, Y.-H., Qin, X., Zhou, X.-C., Cai, Y.-J., Li, Z.-Q., Zhang, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.015 · Cited by 198
Metadata
- Authors
- Corre, J., Labat, E., Espagnolle, N., Hébraud, B., Avet-Loiseau, H., Roussel, M., Huynh, A., Gadelorge, M., Cordelier, P., Klein, B., Moreau, P., Facon, T., Fournié, J.-J., Attal, M., & Bourin, P.
- Venue
- Cancer Research
- Published
- 2012-03-14
- Volume
- 72
- Issue
- 6
- Pages
- 1395-1406
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2117425693
- Cited by
- 103
- References
- 8
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0188
- The paper
- Corre, J., Labat, E., Espagnolle, N., Hébraud, B., Avet-Loiseau, H., Roussel, M., Huynh, A., Gadelorge, M., Cordelier, P., Klein, B., Moreau, P., Facon, T., Fournié, J.-J., Attal, M., & Bourin, P. (2012). Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.